S&P 500   3,145.91 (+0.91%)
DOW   28,015.06 (+1.22%)
QQQ   205.00 (+1.07%)
AAPL   270.71 (+1.93%)
FB   201.05 (+0.85%)
MSFT   151.75 (+1.21%)
GOOGL   1,339.39 (+0.94%)
AMZN   1,751.60 (+0.64%)
CGC   18.65 (+0.27%)
NVDA   212.17 (+1.64%)
MU   47.93 (+2.81%)
BABA   201.89 (+0.95%)
GE   11.10 (+2.87%)
TSLA   335.89 (+1.67%)
T   38.20 (+0.03%)
AMD   39.63 (+0.03%)
ACB   2.43 (-0.41%)
F   9.02 (+1.01%)
PRI   135.68 (+1.03%)
NFLX   307.35 (+1.48%)
BAC   33.67 (+1.75%)
GILD   67.08 (+1.74%)
DIS   147.66 (+0.15%)
S&P 500   3,145.91 (+0.91%)
DOW   28,015.06 (+1.22%)
QQQ   205.00 (+1.07%)
AAPL   270.71 (+1.93%)
FB   201.05 (+0.85%)
MSFT   151.75 (+1.21%)
GOOGL   1,339.39 (+0.94%)
AMZN   1,751.60 (+0.64%)
CGC   18.65 (+0.27%)
NVDA   212.17 (+1.64%)
MU   47.93 (+2.81%)
BABA   201.89 (+0.95%)
GE   11.10 (+2.87%)
TSLA   335.89 (+1.67%)
T   38.20 (+0.03%)
AMD   39.63 (+0.03%)
ACB   2.43 (-0.41%)
F   9.02 (+1.01%)
PRI   135.68 (+1.03%)
NFLX   307.35 (+1.48%)
BAC   33.67 (+1.75%)
GILD   67.08 (+1.74%)
DIS   147.66 (+0.15%)
S&P 500   3,145.91 (+0.91%)
DOW   28,015.06 (+1.22%)
QQQ   205.00 (+1.07%)
AAPL   270.71 (+1.93%)
FB   201.05 (+0.85%)
MSFT   151.75 (+1.21%)
GOOGL   1,339.39 (+0.94%)
AMZN   1,751.60 (+0.64%)
CGC   18.65 (+0.27%)
NVDA   212.17 (+1.64%)
MU   47.93 (+2.81%)
BABA   201.89 (+0.95%)
GE   11.10 (+2.87%)
TSLA   335.89 (+1.67%)
T   38.20 (+0.03%)
AMD   39.63 (+0.03%)
ACB   2.43 (-0.41%)
F   9.02 (+1.01%)
PRI   135.68 (+1.03%)
NFLX   307.35 (+1.48%)
BAC   33.67 (+1.75%)
GILD   67.08 (+1.74%)
DIS   147.66 (+0.15%)
S&P 500   3,145.91 (+0.91%)
DOW   28,015.06 (+1.22%)
QQQ   205.00 (+1.07%)
AAPL   270.71 (+1.93%)
FB   201.05 (+0.85%)
MSFT   151.75 (+1.21%)
GOOGL   1,339.39 (+0.94%)
AMZN   1,751.60 (+0.64%)
CGC   18.65 (+0.27%)
NVDA   212.17 (+1.64%)
MU   47.93 (+2.81%)
BABA   201.89 (+0.95%)
GE   11.10 (+2.87%)
TSLA   335.89 (+1.67%)
T   38.20 (+0.03%)
AMD   39.63 (+0.03%)
ACB   2.43 (-0.41%)
F   9.02 (+1.01%)
PRI   135.68 (+1.03%)
NFLX   307.35 (+1.48%)
BAC   33.67 (+1.75%)
GILD   67.08 (+1.74%)
DIS   147.66 (+0.15%)
Log in

NASDAQ:BTAI - BioXcel Therapeutics Stock Price, Forecast & News

$6.60
+0.25 (+3.94 %)
(As of 12/6/2019 04:00 PM ET)
Today's Range
$6.29
Now: $6.60
$6.65
50-Day Range
$4.00
MA: $5.26
$6.66
52-Week Range
$2.41
Now: $6.60
$12.00
Volume83,387 shs
Average Volume76,903 shs
Market Capitalization$119.03 million
P/E RatioN/A
Dividend YieldN/A
Beta3.09
BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BTAI
CUSIPN/A
Phone475-238-6837

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.49 per share

Profitability

Net Income$-19,270,000.00

Miscellaneous

Employees18
Market Cap$119.03 million
Next Earnings Date3/5/2020 (Estimated)
OptionableNot Optionable

Receive BTAI News and Ratings via Email

Sign-up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter.


BioXcel Therapeutics (NASDAQ:BTAI) Frequently Asked Questions

What is BioXcel Therapeutics' stock symbol?

BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI."

How were BioXcel Therapeutics' earnings last quarter?

BioXcel Therapeutics Inc (NASDAQ:BTAI) posted its earnings results on Thursday, November, 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.02. View BioXcel Therapeutics' Earnings History.

When is BioXcel Therapeutics' next earnings date?

BioXcel Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for BioXcel Therapeutics.

What price target have analysts set for BTAI?

4 Wall Street analysts have issued 1-year target prices for BioXcel Therapeutics' stock. Their forecasts range from $21.00 to $25.00. On average, they expect BioXcel Therapeutics' stock price to reach $22.75 in the next year. This suggests a possible upside of 244.7% from the stock's current price. View Analyst Price Targets for BioXcel Therapeutics.

What is the consensus analysts' recommendation for BioXcel Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioXcel Therapeutics.

What are Wall Street analysts saying about BioXcel Therapeutics stock?

Here are some recent quotes from research analysts about BioXcel Therapeutics stock:
  • 1. According to Zacks Investment Research, "BioXcel Therapeutics Inc. is a clinical stage biopharmaceutical company. It focuses on drug development which utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's product portfolio include BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. BioXcel Therapeutics Inc. is based in the United States. " (9/11/2019)
  • 2. HC Wainwright analysts commented, "Valuation methodology, risks, and uncertainties. We utilize a discounted cash flow (DCF)-based assessment, which yields a total rNPV of $335M for for BXCL701. We thus derive a total enterprise value of $455M, which translates into a price objective of $25.00 based on 18M fully-diluted shares outstanding as of end-3Q19." (1/4/2019)

Has BioXcel Therapeutics been receiving favorable news coverage?

News coverage about BTAI stock has been trending somewhat negative on Friday, InfoTrie reports. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. BioXcel Therapeutics earned a media sentiment score of -1.5 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for BioXcel Therapeutics.

Are investors shorting BioXcel Therapeutics?

BioXcel Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 491,400 shares, an increase of 19.6% from the October 31st total of 410,800 shares. Based on an average trading volume of 71,900 shares, the days-to-cover ratio is currently 6.8 days. Currently, 7.3% of the shares of the company are short sold. View BioXcel Therapeutics' Current Options Chain.

Who are some of BioXcel Therapeutics' key competitors?

What other stocks do shareholders of BioXcel Therapeutics own?

Who are BioXcel Therapeutics' key executives?

BioXcel Therapeutics' management team includes the folowing people:
  • Dr. Vimal D. Mehta Ph.D., Founder, CEO, Pres, Sec. & Director (Age 58)
  • Dr. Frank D. Yocca Ph.D., Chief Scientific Officer (Age 63)
  • Dr. Vincent J. O'Neill M.D., B.Sc., M.R.C.P., Sr. VP & Chief Medical Officer (Age 50)
  • Mr. Richard I. Steinhart MBA, Chief Financial Officer (Age 62)
  • Mr. Chids Mahadevan, VP of Fin. & Chief Accounting Officer (Age 47)

When did BioXcel Therapeutics IPO?

(BTAI) raised $60 million in an initial public offering on Thursday, March 8th 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Who are BioXcel Therapeutics' major shareholders?

BioXcel Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Artemis Investment Management LLP (7.57%), California Public Employees Retirement System (2.01%), Point72 Asset Management L.P. (1.16%), State Street Corp (0.47%), Squarepoint Ops LLC (0.20%) and Strs Ohio (0.05%). Company insiders that own BioXcel Therapeutics stock include Frank Yocca, Peter Mueller, Richard I Steinhart and Vimal Mehta. View Institutional Ownership Trends for BioXcel Therapeutics.

Which major investors are buying BioXcel Therapeutics stock?

BTAI stock was purchased by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP, Point72 Asset Management L.P., State Street Corp, California Public Employees Retirement System, Strs Ohio, Rational Advisors LLC and Squarepoint Ops LLC. Company insiders that have bought BioXcel Therapeutics stock in the last two years include Frank Yocca, Peter Mueller, Richard I Steinhart and Vimal Mehta. View Insider Buying and Selling for BioXcel Therapeutics.

How do I buy shares of BioXcel Therapeutics?

Shares of BTAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BioXcel Therapeutics' stock price today?

One share of BTAI stock can currently be purchased for approximately $6.60.

How big of a company is BioXcel Therapeutics?

BioXcel Therapeutics has a market capitalization of $119.03 million. The company earns $-19,270,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis. BioXcel Therapeutics employs 18 workers across the globe.View Additional Information About BioXcel Therapeutics.

What is BioXcel Therapeutics' official website?

The official website for BioXcel Therapeutics is http://www.bioxceltherapeutics.com/.

How can I contact BioXcel Therapeutics?

BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The company can be reached via phone at 475-238-6837 or via email at [email protected]


MarketBeat Community Rating for BioXcel Therapeutics (NASDAQ BTAI)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  134 (Vote Outperform)
Underperform Votes:  140 (Vote Underperform)
Total Votes:  274
MarketBeat's community ratings are surveys of what our community members think about BioXcel Therapeutics and other stocks. Vote "Outperform" if you believe BTAI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTAI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/6/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel